The company recently completed the P.R.O.O.F preclinical phase, a 12-month study assessing its flowable collagen technology. While the results remain internal and await peer review, Conexeu claims the data provides a foundation for entering the $11 billion medical aesthetics injectable market. CEO Miles Harrison argues that current tools, built for smoothing lines rather than structural restoration, fail to meet the needs of the new patient demographic created by the GLP-1 boom.

Unlike traditional long-cycle pharmaceutical development, Conexeu is aiming for a 510(k) regulatory pathway, targeting a Q1 2027 submission. This strategy relies on proving substantial equivalence to existing devices, a route that would bypass the multi-year clinical trials typically required for new categories. However, the company remains in a precarious early stage; its findings are based on animal models, and the projected market growth for GLP-1-related aesthetic procedures—estimated to hit $2 billion by 2030—remains speculative. Conexeu faces a landscape dominated by industry heavyweights like AbbVie, Eli Lilly, and Galderma, all of which maintain significantly larger footprints in the aesthetics and weight-loss sectors.